GameChangers: The Latest on Mifepristone
GameChangers: The Latest on Mifepristone
On June 13th, the US Supreme Court ruled in favor of the United States in a case that challenged the availability of mifepristone. This episode provides a straightforward recap of the court ruling and what it means for pharmacists.
The GameChanger: Pharmacists should understand legal boundaries and ethical considerations surrounding medications like mifepristone to provide safe, compliant, and patient-centered care.
Upon successful completion of this course, learners should be able to:
1. Describe the historical context and legal evolution of mifepristone regulation by the FDA, including key changes and their implications for pharmacy practice.
2. Identify the ethical responsibilities and state and federal legal requirements when dispensing medications such as mifepristone.
Guest
David Brushwood, RPh, JD
Senior Lecturer
University of Wyoming
David Brushwood has no relevant financial relationships to disclose.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: June 24, 2024
Planned Expiration Date: June 24, 2025
Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
| Duration | 0h 30m |
|---|---|
| Topic Designator | Disease State/Drug Therapy |
| ACPE | Yes |
| ACPE Topic | 03 Law |
| Role | Pharmacist |
| Media-Type | Podcast |
| Release Date | 6/24/24 |
| CEUs | 0.05 |
| Rating | 4 |
| ACPE Number | 0107-0000-24-209-H03-P |
